#United States #Acute Myeloid Leukemia #Natick #Pillar Biosciences #oncoReveal Rapid AML Panel

Pillar Biosciences Unveils oncoReveal® Rapid AML Panel

In an innovative move for cancer research, Pillar Biosciences has launched the oncoReveal® Rapid AML Panel, a next-generation sequencing (NGS) DNA panel aimed at providing faster and more efficient genomic insights for acute myeloid leukemia (AML). As an aggressive blood cancer, AML demands timely molecular characterization, and this new tool is tailored to meet those urgent needs in laboratory research settings.

Understanding the Importance of Rapid Insights in AML

Acute myeloid leukemia is characterized by rapid progression and requires swift identification of genetic abnormalities to guide treatment options. The introduction of the oncoReveal Rapid AML Panel supports researchers by streamlining the workflow from sample preparation to library creation. This system effectively reduces the time spent on batching samples, allowing for individual rapid processing. The panel can produce essential genomic findings in under 8.5 hours, a crucial metric for labs that need to make quick decisions based on genetic data.

Dr. ShiPing Zou, Senior Director of Product Management at Pillar Biosciences, emphasized the pivotal role of speed in AML molecular workflows. He remarked, "With the oncoReveal Rapid AML Panel, our goal was to facilitate fast yet reliable analysis, focusing on guideline-informed genes crucial for AML research. The efficient processing not only increases throughput but also enhances the quality of insights that can be gathered from each sample."

Key Features and Benefits

The oncoReveal Rapid AML Panel boasts several noteworthy features designed for optimized research performance:

• - Streamlined Workflow: It's specifically designed for rapid sample-to-library preparation with no batching required, which significantly speeds up laboratory processes.
• - Guideline-Informed Content Selection: The panel aligns with the latest recommendations from authoritative bodies, ensuring that the genes targeted for amplification are relevant and scientifically-backed.
• - Hotspot Coverage of Critical Genes: The panel focuses on essential mutations including FLT3, IDH1, IDH2, KIT, KRAS, NPM1, and NRAS, among others, which are vital for understanding and treating AML effectively.
• - Robust Performance in Challenging Regions: The technology behind the panel includes features that enable detection of long FLT3 internal tandem duplications, which are often difficult to analyze but critical in AML diagnosis.

The Global Impact of AML

According to the American Cancer Society, an estimated 22,720 people will be diagnosed with AML in the United States alone in 2026, with 11,500 expected to perish from the disease that same year. Globally, analyses indicate that AML incidence has seen a rise, with approximately 144,650 new cases reported worldwide in 2021.

The launch of the oncoReveal Rapid AML Panel comes at a crucial time, offering laboratories an opportunity to enhance their capabilities in AML research and accelerate the discovery process for new treatment pathways.

Availability and Next Steps

The oncoReveal® Rapid AML Panel is now available for laboratories specializing in leukemia research. Interested parties are encouraged to contact Pillar Biosciences to explore how this innovative panel can cater to their research objectives.

For more details on how to integrate this panel into your AML investigation workflows, visit pillarbiosci.com and connect with the company on LinkedIn.

Important Note

The oncoReveal Rapid AML Panel is intended for research use only and should not be utilized for diagnostic procedures or clinical decision-making. Performance characteristics can vary based on specimen type, input quality, and laboratory workflows.